O
OrbiMed Portfolio holdings
AUM
$3.98B
This Quarter Return
+7.9%
1 Year Return
+13.05%
3 Year Return
+159.74%
5 Year Return
+207.27%
10 Year Return
+1,027.33%
AUM
$3.98B
AUM Growth
+$3.98B
(-4.5%)
Cap. Flow
-$356M
Cap. Flow
% of AUM
-8.96%
Top 10 Holdings %
Top 10 Hldgs %
49.18%
Holding
122
New
13
Increased
19
Reduced
24
Closed
22
Top Buys
| 1 |
CAI
Caris Life Sciences, Inc. Common Stock
CAI
|
$81.1M |
| 2 |
UnitedHealth
UNH
|
$42.1M |
| 3 |
Roivant Sciences
ROIV
|
$31.3M |
| 4 |
Vertex Pharmaceuticals
VRTX
|
$22.4M |
| 5 |
CytomX Therapeutics
CTMX
|
$19.2M |
Top Sells
| 1 |
Pfizer
PFE
|
$97.6M |
| 2 |
RAPT Therapeutics
RAPT
|
$91.9M |
| 3 |
Ionis Pharmaceuticals
IONS
|
$76.6M |
| 4 |
Neurocrine Biosciences
NBIX
|
$62.4M |
| 5 |
SWTX
SpringWorks Therapeutics
SWTX
|
$41.9M |
Sector Composition
| 1 | Healthcare | 99.67% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SVA
1
DELISTED
Sinovac Biotech, Ltd
SVA
| $334M | 8.34% | 2,718,735 | – | – |
|
2
Boston Scientific
BSX
$156B
| $302M | 7.55% | 2,813,200 | – | – |
|
3
Eli Lilly
LLY
$657B
| $263M | 6.57% | 337,600 | – | – |
|
4
Edgewise Therapeutics
EWTX
$1.51B
| $203M | 5.08% | 15,518,492 +496,771 | +3% | +$6.51M |
|
5
Enliven Therapeutics
ELVN
$1.2B
| $160M | 3.99% | 7,959,538 | – | – |
|
6
Intuitive Surgical
ISRG
$170B
| $158M | 3.95% | 291,000 | – | – |
|
7
ARS Pharmaceuticals
SPRY
$1.15B
| $145M | 3.61% | 8,288,510 | – | – |
|
8
Stryker
SYK
$150B
| $142M | 3.55% | 359,200 | – | – |
|
9
Edwards Lifesciences
EW
$47.8B
| $134M | 3.34% | 1,708,000 +176,000 | +11% | +$13.8M |
|
10
argenx
ARGX
$43.6B
| $115M | 2.86% | 208,000 +1,300 | +0.6% | +$717K |
|
11
Alnylam Pharmaceuticals
ALNY
$58.5B
| $111M | 2.78% | 341,900 -4,200 | -1% | -$1.37M |
|
|
12
UnitedHealth
UNH
$281B
| $105M | 2.62% | 336,300 +135,100 | +67% | +$42.1M |
|
13
Natera
NTRA
$23.1B
| $100M | 2.5% | 593,434 +46,434 | +8% | +$7.84M |
|
|
14
Vertex Pharmaceuticals
VRTX
$100B
| $93.6M | 2.34% | 210,287 +50,387 | +32% | +$22.4M |
|
15
Tenet Healthcare
THC
$16.3B
| $81.8M | 2.04% | 465,000 | – | – |
|
|
CAI
16
Caris Life Sciences, Inc. Common Stock
CAI
$10.8B
| $81.1M | 2.03% | +3,034,858 | New | +$81.1M |
|
17
Disc Medicine
IRON
$2.07B
| $74.9M | 1.87% | 1,415,020 | – | – |
|
18
ArriVent BioPharma
AVBP
$776M
| $65.9M | 1.65% | 3,027,328 | – | – |
|
|
SION
19
Sionna Therapeutics, Inc. Common Stock
SION
$1.09B
| $64.3M | 1.61% | 3,704,959 | – | – |
|
|
UPB
20
Upstream Bio, Inc. Common Stock
UPB
$923M
| $62.5M | 1.56% | 5,693,589 | – | – |
|
|
21
Neurocrine Biosciences
NBIX
$13.8B
| $55.1M | 1.38% | 438,540 -496,100 | -53% | -$62.4M |
|
22
Integer Holdings
ITGR
$3.78B
| $53.3M | 1.33% | 433,400 -229,100 | -35% | -$28.2M |
|
23
Avidity Biosciences
RNA
$5.99B
| $51.5M | 1.29% | 1,812,886 | – | – |
|
24
CG Oncology
CGON
$2.04B
| $48.8M | 1.22% | 1,877,850 -594,144 | -24% | -$15.4M |
|
25
SI-BONE Inc
SIBN
$719M
| $48.5M | 1.21% | 2,578,979 -863,874 | -25% | -$16.3M |
|